CRM
Salesforce, Inc.
CRM offers stronger valuation, but that advantage does not outweigh its weaker overall profile.
LLY
Eli Lilly and Company
LLY has the edge over CRM overall, supported by stronger modeled upside and stronger fundamentals.
CRM Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Stable |
CRM's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
CRM PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 20x | $218 | — |
| Cheap | 36x | $393 | +80% |
| Fair | 70x | $766 | +252% |
| Expensive | 293x | $3,206 | +1374% |
Historical ranges are pointers, not guarantees.
CRM has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
CRM Forward outlook
There aren't enough analyst estimates for CRM to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
CRM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $10.96 | +59% |
| Q2 2026 | $8.63 | +35% |
| Q1 2026 | $7.80 | +23% |
| Q4 2025 | $7.49 | +23% |
| Q3 2025 | $6.88 | +20% |
| Q2 2025 | $6.39 | +15% |
| Q1 2025 | $6.36 | +51% |
| Q4 2024 | $6.08 | +131% |
CRM's earnings per share have climbed steadily: $10.96 over the past year, up 59% from the year before, and higher year over year for 13 quarters in a row. Its recent earnings include one-off gains.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over CRM on earnings, with stronger typical year-over-year growth.
CRM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11.3B | +11% |
| Q2 2026 | $11.1B | +13% |
| Q1 2026 | $11.2B | +12% |
| Q4 2025 | $10.3B | +8.6% |
| Q3 2025 | $10.2B | +9.8% |
| Q2 2025 | $9.8B | +7.6% |
| Q1 2025 | $10B | +7.6% |
| Q4 2024 | $9.4B | +8.3% |
CRM's revenue has grown year over year every quarter since late 2020: $11.3B last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 21% | -2.2 points |
| Q2 2026 | 21% | +1.3 points |
| Q1 2026 | 17% | -1.5 points |
| Q4 2025 | 21% | +1.3 points |
| Q3 2025 | 23% | +3.7 points |
| Q2 2025 | 20% | +1.1 points |
| Q1 2025 | 18% | +0.7 points |
| Q4 2024 | 20% | +2.8 points |
CRM's operating margin was 21% last quarter, down 2.2 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over CRM on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over CRM on profitability, with a higher operating margin.
CRM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $1.1B | +81% |
| Q2 2026 | $6.6B | +4.1% |
| Q1 2026 | $5.3B | +39% |
| Q4 2025 | $2.2B | +22% |
| Q3 2025 | $605M | -20% |
| Q2 2025 | $6.3B | +3.5% |
| Q1 2025 | $3.8B | +17% |
| Q4 2024 | $1.8B | +30% |
CRM has the edge over LLY on cash flow, with more consistent year-over-year improvement.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY generated $19.7B in free cash flow over the past year, up 112% from the year before.
CRM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -5.7% | -50M shares |
| 1 year | -15% | -141M shares |
| 3 years | -17% | -165M shares |
| 5 years | -14% | -129M shares |
| Available history | -6.6% | -58M shares |
CRM has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $84M |
| Q2 2026 | $27.2B |
| Q1 2026 | $3.9B |
| Q4 2025 | $3.8B |
| Q3 2025 | $2.2B |
| Q2 2025 | $2.6B |
| Q1 2025 | $76M |
| Q4 2024 | $1.3B |
CRM spent $35.1B buying back its own shares over the past year, about six times what it spent the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
CRM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.5x | Moderate |
| Q2 2026 | 2.4x | Moderate |
| Q1 2026 | 0.6x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.2x | Net Cash |
| Q2 2025 | -0.2x | Net Cash |
| Q1 2025 | -0.0x | Net Cash |
| Q4 2024 | 0.0x | Very low |
CRM's net debt is about 2.5 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over CRM on leverage, with a lower net debt burden relative to earnings.
CRM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.7 | Neutral |
| Stochastic | 44.2 | Neutral |
CRM's weekly RSI is 51 (neutral) and its Stochastic is 44 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
CRM PE vs Technology Sector
| Metric | CRM | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 28x | 29% below |
| PE % | 2 | 35 | 33 pts below |
CRM has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
CRM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $230.9 | 5.8% below |
| 20 week MA | $214.7 | 1.3% above |
| 50 week MA | $206.8 | 5.2% above |
| 100 week MA | $239.7 | 9.2% below |
| 200 week MA | $242.0 | 10% below |
CRM's trend is mixed: it's above two of its five weekly moving averages, and 10% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over CRM on trend strength, trading above more of its moving averages.
CRM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $165.0 | $225.8 | +37% |
| 2021 | $225.8 | $253.1 | +12% |
| 2022 | $253.1 | $129.4 | -49% |
| 2023 | $129.4 | $263.1 | +103% |
| 2024 | $263.1 | $338.5 | +29% |
| 2025 | $338.5 | $266.1 | -21% |
| 2026 YTD | $266.1 | $217.6 | -18% |
CRM's yearly returns have swung widely, from +103% in 2023 to −49% in 2022. It's down 18% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over CRM on returns for 2026, with the stronger performance.